Search - tctmd.com

Displaying 61 - 80 of 412

Sort: Relevancy | Date

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

L.A. McKeown

November 25, 2024

News Conference News AHA 2024

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

L.A. McKeown

November 22, 2024

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

Presentation AHA 2024

Randomized Study Comparing PK/PD Properties of a Novel Intranasal Formulation of Bumetanide to Oral and IV Formulations

Presenter: Daniel Bensimhon

November 18, 2024

News Conference News AHA 2024

Nasal Bumetanide Safe, Effective in Healthy Adults

Yael L. Maxwell

November 18, 2024

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Shelley Wood

November 17, 2024

Presentation AHA 2024

Routine spironolactone in Acute Myocardial Infarction, results from the CLEAR SYNERGY OASIS 9 trial

Presenter: Sanjit S Jolly

November 17, 2024

Presentation AHA 2024

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Presenter: Milton Packer

November 16, 2024

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Features

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

Todd Neale

November 13, 2024

News Opinion CV Team Dispatch

October 2024 Dispatch for the CV Team

L.A. McKeown

October 25, 2024

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

L.A. McKeown

October 04, 2024

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

L.A. McKeown

October 02, 2024

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

News Daily News

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

L.A. McKeown

October 01, 2024

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

Todd Neale

October 01, 2024

News Daily News

HFSA Cancels Annual Meeting Due to Looming Hurricane

L.A. McKeown

September 26, 2024

Advertisement

November 2024 Dispatch for the CV Team

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Randomized Study Comparing PK/PD Properties of a Novel Intranasal Formulation of Bumetanide to Oral and IV Formulations

Nasal Bumetanide Safe, Effective in Healthy Adults

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Routine spironolactone in Acute Myocardial Infarction, results from the CLEAR SYNERGY OASIS 9 trial

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

October 2024 Dispatch for the CV Team

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

HFSA Cancels Annual Meeting Due to Looming Hurricane

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content